Nektar Therapeutics (NKTR) Receivables (2010 - 2025)

Nektar Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• In Q4 2025, Receivables fell 9.09% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 9.09% YoY), while the FY2025 annual figure was $1.0 million, down 9.09% from the prior year.
• Receivables for Q4 2025 stood at $1.0 million, up from $200000.0 in the prior quarter.
• The five-year high for Receivables was $30.2 million in Q1 2022, with the low at $200000.0 in Q3 2025.
• The 5-year median for Receivables is $3.6 million (2024), against an average of $10.9 million.
• The sharpest annual moves came in 2023 and 2024: Receivables slumped 90.09% in 2023, then advanced 20.77% in 2024.
• Nektar Therapeutics' Receivables stood at $23.9 million in 2021, then sank by 72.04% to $6.7 million in 2022, then slumped by 74.48% to $1.7 million in 2023, then slumped by 35.48% to $1.1 million in 2024, then dropped by 9.09% to $1.0 million in 2025.
• Business Quant data shows NKTR's Receivables at $1.0 million in Q4 2025, $200000.0 in Q3 2025, and $1.1 million in Q4 2024.